G2A Increase Focus FDA 483

QSIT VALIDATION WORKSHEET

Item#	Goal/Outcome												
G2A	Increase the focus of FDA 483	listed Quality System deficiencies on key elements of the											
(Activity 1)		System with linkages to the remaining subsystems.											
Term ¹	Type of activity (test or analysis)	Parameter(s) to be measured											
Short	Test	1. Comparison of FDA 483 items to the steps in the QSIT Handbook flowcharts. 2. Subsystems associated with QSIT FDA 483 items vs non-QSIT FDA 483 items. 3. QSIT OAI rate vs non-QSIT OAI rate.											
Scope and nature of the process to be	investigators in DEN-DO, LOS-DO a	nd having a target completion date of 12/31/98, QSIT trained and MIN-DO are to conduct medical device Quality System inspections investigators are participating in the Study. Each investigator is to inspections.											
followed 2	HFZ-320. The QS regulation FDA 48 Handbook. The flowchart steps corres evaluated when performing a QSIT in	DA 483s for the QSIT Study inspections will be reviewed by C. Tylka, 3 items will be compared to the steps of the flowcharts in the QSIT pond to the key elements of the firm's Quality System that are to be spection. The results of the reviews will be tabulated and assessed. be flowchart steps will indicate that the QSIT FDA 483 items focused on tems.											
	subsystems associated with the 10 mo conducted during the period 6/97-6/98 Needed Improvement. However, they evaluation. The FDA 483 items from maintained by HFZ-305. The results withe 4 major subsystems (Management the major subsystems of the regulation	O most prevalent QSIT FDA 483 items will also be compared to the st prevalent QS regulation FDA 483 items from non-QSIT inspections B. Design Control deficiencies during this period were listed as Areas of were tracked in the CDRH database and will be included in this non-QSIT inspections will be identified from the FDA483 database will be tabulated and assessed. The correspondence of FDA 483 items to a Design, CAPA and PAPC) will indicate that the FDA 483 focused on an An increase in the correspondence of QSIT FDA 483 items vs non-increase in focus on the major subsystems.											
	using the QSIT Draft Part V of the Coperformed during FY 98. The OAI rat the inspection on the assessment of the inspections should also contain items	spections, based on classifications by QSIT trained Compliance Officers impliance Program 7382.830, will be compared to non-QSIT inspections e for FY 98 will be obtained from HFZ-305. QSIT was designed to focuse key elements of the Quality System. FDA 483s resulting from the which focus on those key elements. Inspections conducted using QSIT, ments, should yield at least the same or greater violation (OAI) rate as QSIT approach.											
	Overall responsibility for this activity: G. Layloff (HFR-SW450) and T. Wells (HFZ-332)												
Acceptance criteria (if known)	 The majority of the FDA 483 item There is more of a correspondence regulation then non-QSIT FDA 4 	ns correspond to the steps of the QSIT flowchart. e of the QSIT FDA 483 items with the major subsystems of the QS											
the goal/outcome	e activity measures/confirms how well has been met. ³ (strengths and is validation activity)	This activity provides a direct and objective measurement on whether QSIT FDA 483s focus on the key Quality System elements. It indirectly compares the focus of QSIT FDA 483s to non-QSIT FDA 483s.											
	e activity represents one of the best easuring the accomplishment of the	This pre-deployment activity will demonstrate if the QSIT FDA 483s were focused. It will indirectly measure whether or not the FDA 483 focus has increased.											

Rev.12/18/98

¹ Short term = pre-deployment event, long-term = post-deployment event
² Describe who, what, where, when, and how. Include an identification of baseline data that may be useful for comparing QSIT performance to the existing approach.

QSIT VALIDATION ACTIVITY REPORT

Item#	Goal/Outcome										
G2A		sted Quality System deficiencies on key elements of the System with linkages to the remaining subsystems.									
Activity #	Type of activity (test or analysis)	Parameter(s) to be measured									
1	Test	1. Comparison of FDA 483 items to the steps in the QSIT Handbook flowcharts. 2, Subsystems associated with QSIT FDA 483 items vs non-QSIT FDA 483 items. 3. QSIT OAI rate vs non-QSIT QAI rate.									
Acceptance Criteria	2. There is more of a correspondence regulation then non-QSIT FDA 48										
		s is at least equal to or greater then that of non-QSIT inspections.									
Summary of Results	to 2/19/99 in order to allow for the com	98. It had a target completion date of 12/31/98. This date was extended appletion of at least 40 total QSIT inspections. During the Study period, in DEN-DO, LOS-DO and MIN-DO, conducted medical device Quality									
	A total of 42 QSIT inspections were co 200 items were issued during those insp	nducted during the Study. A total of 28 FDA 483s containing a total of pections.									
	1	320 and the individual FDA 483 items were compared to the steps of The flowchart steps correspond to the key elements of the major									
	A tabulation of the results is attached.										
		ns were found to match the QSIT Handbook flowchart steps. Of the nked to CAPA and PAPC flowchart steps. The remaining 12 items steps.									
	This activity has demonstrated that the subsystems of the Quality System.	QSIT FDA 483 items focused on the key elements of the major									
	Part 2 A comparison of the 10 most prevalent items to correspond more with the major	FDA 483 items from QSIT and non-QSIT inspections found the QSIT or subsystems as follows:									
	QSIT Inspections: Management 40%, CAPA 30%, PAPC 20%, and D&R 10% Non-QSIT Inspections: CAPA 50%, PAPC 30%, and D&R 20%										
	This increase in the correspondence inc	dicates an increase in focus on the major subsystems.									
	7382.830, by QSIT trained Compliance	ssified OAI, using the QSIT Draft Part V of the Compliance Program e Officers. The OAI rate for QSIT inspections classified in this manner is 16%. This equates to an increase in the OAI rate of 31%.									
	The findings do [X] do not [] m	eet the acceptance criteria for this activity.									
Additional Comments	-										
Activity Chan	ipion(s) Georgia Layloff (l	HFR-SW450) and Timothy Wells (HFZ-332)									

Attachment 1 - Item # G2A (Activity 1)

Part 1

FDA483 Review Results (QS Regulation Deficiencies)

	>				2.1																					
FOF4J	12	4	0	8	S	0	12	16			3	0	0	1	2	2	2	-1	0	2	1	7	4	0		
3 D																								-1-		
m 0 M					,1		1																			
7.Um							1																			
.3 .4.				-				-																		
u⊈m.e.	-1																						1			
. 2 m 3								1															-			
3 1 B 3	3			2				1																		
W. ₹. 4. 10.	-																									
\$ 4 F																					_	2				
√ (g) 4.																										
910 C																										
70.0 -																										
¹ 2,0.4 }=								1																		
7.E.																										
																							1			
2 2 A B 1 1	1																									
																				_						
-0.4							2	1							٠					-						
. Э. Э. Э. Э.		2		2			1	2									2		_	 		-				
1 D 2		-						2	•	-								_		H		-		-		
(1) (1) (1) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4					-	_											_		-	-	-	_	_			
O N																		-			_					
- Θ C				1	_		2	2		_	_							-	\vdash		_	-		L		
	1										_						_		_		-	2	_			
A 24 B				1		_	-	-							_	_	-		-			-	-	_		
3. 4.4.	S.							-		_	-				_	_	_	-	-	-	-	-		_		
-{A (0)						_				ļ		ļ	_	<u> </u>	_	-			-	-	-	-	-	-		
1. 1. 2 1. 2						_					_	_	_		_		_	-	-	-	_	-	-	-		
<u>*</u> (A				ļ	<u> - </u>		_	7												Ļ	Ļ	-		Ļ		
ООДЩ		7	3a	33	4a	4	2	9			2	<u></u>	4	\ <u>\</u>	9		∞	0	0	E	[2]	2	<u> </u>	<u> </u>		
	Σ	Z O Z H								Δ	ш	S	→ (ב כ	Z .											

5

O H & H	12	=	0	-	2	6	7	3	4	1	,	0	0	29	-	8	3	2	2	6	77		200
^ω Φ'ώ;	7													-							20.		4
^ω Ω Ψ ;	-													-									Ś
م. U، ظ																						* 6	B
√ m′ ₄ .					-		3												-		-		
т ш т				-										-						[77		9
_т , д , С														3		1							9
£ B □		-												_		1							01
m 4 4 €.4.							1							-				-			3		6
m ď F.		-				-								_{لك}		m	-				57		15
5 Ū 4																			-		-		2
400		-				2								7				-					9
иД:0- ; <u>-</u>														-									-
40'4.							_																2
n m c	-	2				2																An.	v
ca.M.T.									7														,,
A 4분	-													-									~
O 4														2									0
⊢ Δ <u>.</u>																					5		6
Q Ω		-				-								-	:						1		1.5
-05:	-													-									0
- 0.5 x							-							4			-						×
-JOB		2				3		-	-					-									5-
_ o	-	-												-					T		4		-
i i i i i i i i i i i i i i i i i i i														2	-								4
T. A. 4- () ;	3													-									10
4 €	Γ	7					-																1
. 7 A L								7								-			T		=		-
-†- 4 :	-								-					1		-							\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
О[О О і́іі]	-	7	m	4	2	9	1	∞	6	2		la	12	7	3a	32	4	1	9	1	er		1. T. T. T.
one in with makenin men great (IRE) - and fine (II)	1	∢	<u>е</u> Д,	≺		1	а	4		4		d.	≺	<u>,</u>	<u>. </u>	٠	<u>.l</u>	<u></u>	Л	1	Other		Ė

Linkage between PAPC and D&R ² Linkage between CAPA and D&R

Attachment 1 Item # G2A (Activity 1)

Part 2

Review of the QS Regulation FDA 483 items from QSIT and non-QSIT inspections found the 10 most prevalent items to be associated with the following subsystems:

Documents & Records (20%) Non-QSIT inspections CAPA (50%) PAPC (30%) Documents & Records (10%) Management (40%) **QSIT** Inspections CAPA (30%) PAPC (20%)

Part 3

The following QSIT inspections were classified OAI, using the QSIT Draft Part V of the Compliance Program, by the QSIT trained

Compliance Officers who participated in the Study:
1. 1A1
2. 1A4
3. 1C3
6. 1D2
9. 3B4

There were 42 inspections conducted during the Study. The QAI rate for QSIT inspections using the QSIT Draft Part V was 21%.

The OAI rate for FY 98 was 16%.